Bcl-xL Degrader

XZ739 is a potent and selective BCL-XL PROTAC degrader with a DC₅₀ of 2.5 nM. XZ739 recruits CRBN to ubiquitinate and degrade BCL-XL via the ubiquitin-proteasome system. XZ739 also induces cell cycle arrest and caspase-mediated apoptosis. XZ739 can be used in research related to T-cell acute lymphoblastic leukemia and cholangiocarcinoma.

PZ671 is a Bcl-xL PROTAC degrader that recruits cereblon, with a DC₅₀ of 0.9 nM in MOLT-4 T-ALL cells. PZ671 induces apoptosis via activation of caspase-3 and cleavage of PARP, and exhibits antitumor activity in T-cell acute lymphoblastic leukemia and small cell lung cancer models. PZ671 can be used for the research of T-cell acute lymphoblastic leukemia and small cell lung cancer.

PZ703b is a Bcl-xl PROTAC degrader that induces apoptosis and inhibits cancer cell proliferation. PZ703b can be used for the research of bladder cancer research.

WH244 is a BCL-xL and BCL-2 PROTAC degrader with DC₅₀ values of 0.6 nM and 7.4 nM, and K_d values of 6.14 nM and 3.1 nM, respectively. WH244 kills cancer cells dependent on BCL-xL and BCL-2 for survival. WH244 is applicable to relevant research on leukemia.

XZ338 is a highly potent and selective BCL-XL PROTAC degrader derived from A-1331852 (HY-19741), with a DC₅₀ of 0.43 nM in MOLT‑4 cells. XZ338 induces the formation of a ternary complex with BCL-XL and VHL E3 ligase, mediates target protein degradation via the ubiquitin-proteasome system, and exhibits significantly weaker degradation activity in platelets than in tumor cells. XZ338 possesses anti-cancer activity. XZ338 can be used in the research of T-cell acute lymphoblastic leukemia (T-ALL).

PZ703b TFA is a Bcl-xl PROTAC degradation agent that induces apoptosis and inhibits cancer cell proliferation for bladder cancer research.

PROTAC Bcl-2/Bcl-xL Degrader-1 is a Bcl-2/Bcl-xL PROTAC degrader with a DC₅₀ of 11.28 nM against Bcl-xL. PROTAC Bcl-2/Bcl-xL Degrader-1 promotes ubiquitination and degradation of Bcl-2/Bcl-xL. It exhibits anticancer activity against acute lymphoblastic leukemia. PROTAC Bcl-2/Bcl-xL Degrader-1 can be used in the research of BCL-2-mediated or BCL-2-dependent diseases.

EGFR-IN-197 is an EGFR inhibitor with IC₅₀ values of 19.5 nM and 12.0 nM against EGFR^L858R/T790M and EGFR^{L858R/T790M/C797S}, respectively. EGFR-IN-197 arrests the cell cycle of NCI-H1975 cells at the G2/M phase, while inhibiting their proliferation, colony formation and migration; it also inhibits mitochondrial translocation and upregulates mitochondrial H₂S levels. EGFR-IN-197 disrupts anti-apoptotic signaling pathways by regulating apoptosis-related proteins; it induces DNA damage and activates pro-apoptotic pathways to trigger apoptosis. EGFR-IN-197 can be used in studies related to non-small cell lung cancer (NSCLC).

PROTAC BCL-xL/BCL-w Degrader 1 is a selective BCL-xL/BCL-w PROTAC degrader. PROTAC BCL-xL/BCL-w Degrader 1 promotes ubiquitination and degradation of BCL-xL and BCL-w, without affecting BCL-2. PROTAC BCL-xL/BCL-w Degrader 1 can be used for the research of Hodgkin lymphoma.

PZ15227 is a potent and selective Bcl-XL PROTAC degrader with a DC₅₀ of 46 nM, and its K_i values for Bcl-XL, Bcl-2 and Bcl-w are 1.90 nM, 3.52 nM and >1 mM, respectively. PZ15227 recruits Bcl-XL to CRBN, induces polyubiquitination of Bcl-XL and promotes its proteasome-dependent degradation, thereby selectively killing senescent cells that rely on Bcl-XL for survival without causing severe thrombocytopenia. PZ15227 can be used for research related to age-related diseases, aging and renal cancer.

BCL-xL ligand 2 is a ligand for BCL-xL. BCL-xL ligand 2 can be conjugated with E3 ligase Ligand (HY-138793) and linker to synthesize Bcl-xL PROTAC degrader PZ671 (HY-174876).

PZ703b hydrochloride is a Bcl-xl PROTAC degrader that induces apoptosis and inhibits cancer cell proliferation. PZ703b hydrochloride can be used for the research of bladder cancer research.

PROTAC Bcl-xL degrader-4 is a Bcl-xL PROTAC degrader. PROTAC Bcl-xL degrader-4 exhibits cytotoxicity against hepatocellular carcinoma cells, inhibits their migration and colony formation, and shows low cytotoxicity toward normal cells. PROTAC Bcl-xL degrader-4 induces apoptosis by reducing mitochondrial membrane potential and activating the MAPK signaling pathway. PROTAC Bcl-xL degrader-4 significantly suppresses tumor growth in xenograft tumor mouse models. PROTAC Bcl-xL degrader-4 can be used in hepatocellular carcinoma-related research.